These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 30204862)

  • 21. Functional Insights in PLS3-Mediated Osteogenic Regulation.
    Zhong W; Neugebauer J; Pathak JL; Li X; Pals G; Zillikens MC; Eekhoff EMW; Bravenboer N; Zhang Q; Hammerschmidt M; Wirth B; Micha D
    Cells; 2024 Sep; 13(17):. PubMed ID: 39273077
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MicroRNA-124 regulates osteoclast differentiation.
    Lee Y; Kim HJ; Park CK; Kim YG; Lee HJ; Kim JY; Kim HH
    Bone; 2013 Oct; 56(2):383-9. PubMed ID: 23867221
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Teriparatide Treatment in Patients With WNT1 or PLS3 Mutation-Related Early-Onset Osteoporosis: A Pilot Study.
    Välimäki VV; Mäkitie O; Pereira R; Laine C; Wesseling-Perry K; Määttä J; Kirjavainen M; Viljakainen H; Välimäki MJ
    J Clin Endocrinol Metab; 2017 Feb; 102(2):535-544. PubMed ID: 27732335
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Piperine alleviates osteoclast formation through the p38/c-Fos/NFATc1 signaling axis.
    Deepak V; Kruger MC; Joubert A; Coetzee M
    Biofactors; 2015; 41(6):403-13. PubMed ID: 26627060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorption.
    Luo J; Yang Z; Ma Y; Yue Z; Lin H; Qu G; Huang J; Dai W; Li C; Zheng C; Xu L; Chen H; Wang J; Li D; Siwko S; Penninger JM; Ning G; Xiao J; Liu M
    Nat Med; 2016 May; 22(5):539-46. PubMed ID: 27064449
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The chromatin remodeling factor Arid1a cooperates with Jun/Fos to promote osteoclastogenesis by epigenetically upregulating Siglec15 expression.
    Zhang Y; Sun H; Huang F; Chen Y; Ding X; Zhou C; Wu Y; Zhang Q; Ma X; Wang J; Yue R; Shen L; Sun X; Ye Z
    J Bone Miner Res; 2024 Jul; 39(6):775-790. PubMed ID: 38477755
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bone: Role for PLS3 in X-linked osteoporosis revealed.
    Greenhill C
    Nat Rev Endocrinol; 2013 Dec; 9(12):692. PubMed ID: 24146029
    [No Abstract]   [Full Text] [Related]  

  • 28. Novel PLS3 variants in X-linked osteoporosis: Exploring bone material properties.
    Balasubramanian M; Fratzl-Zelman N; O'Sullivan R; Bull M; Fa Peel N; Pollitt RC; Jones R; Milne E; Smith K; Roschger P; Klaushofer K; Bishop NJ
    Am J Med Genet A; 2018 Jul; 176(7):1578-1586. PubMed ID: 29736964
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Apolipoprotein E plays crucial roles in maintaining bone mass by promoting osteoblast differentiation via ERK1/2 pathway and by suppressing osteoclast differentiation via c-Fos, NFATc1, and NF-κB pathway.
    Noguchi T; Ebina K; Hirao M; Otsuru S; Guess AJ; Kawase R; Ohama T; Yamashita S; Etani Y; Okamura G; Yoshikawa H
    Biochem Biophys Res Commun; 2018 Sep; 503(2):644-650. PubMed ID: 29906458
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Mäkitie RE; Niinimäki T; Suo-Palosaari M; Kämpe A; Costantini A; Toiviainen-Salo S; Niinimäki J; Mäkitie O
    Front Endocrinol (Lausanne); 2020; 11():393. PubMed ID: 32655496
    [No Abstract]   [Full Text] [Related]  

  • 31. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
    Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
    Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diarylheptanoid from Curcuma comosa Roxb. suppresses RANKL-induced osteoclast differentiation by decreasing NFATc1 and c-Fos expression via MAPK pathway.
    Chawalitpong S; Sornkaew N; Suksamrarn A; Palaga T
    Eur J Pharmacol; 2016 Oct; 788():351-359. PubMed ID: 27523282
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transgenic mice overexpressing soluble osteoclast differentiation factor (sODF) exhibit severe osteoporosis.
    Mizuno A; Kanno T; Hoshi M; Shibata O; Yano K; Fujise N; Kinosaki M; Yamaguchi K; Tsuda E; Murakami A; Yasuda H; Higashio K
    J Bone Miner Metab; 2002; 20(6):337-44. PubMed ID: 12434161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 35. REV-ERB agonism suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss partially via FABP4 upregulation.
    Song C; Tan P; Zhang Z; Wu W; Dong Y; Zhao L; Liu H; Guan H; Li F
    FASEB J; 2018 Jun; 32(6):3215-3228. PubMed ID: 29401617
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DDR2 (discoidin domain receptor 2) suppresses osteoclastogenesis and is a potential therapeutic target in osteoporosis.
    Zhang Y; Su J; Wu S; Teng Y; Yin Z; Guo Y; Li J; Li K; Yao L; Li X
    Sci Signal; 2015 Mar; 8(369):ra31. PubMed ID: 25805889
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The systemic bone protective effects of Gushukang granules in ovariectomized mice by inhibiting osteoclastogenesis and stimulating osteoblastogenesis.
    Wang Q; Zhao Y; Sha N; Zhang Y; Li C; Zhang H; Tang D; Lu S; Shi Q; Wang Y; Shu B; Zhao D
    J Pharmacol Sci; 2018 Mar; 136(3):155-164. PubMed ID: 29501580
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Unique expression and critical role of metallothionein 3 in the control of osteoclastogenesis and osteoporosis.
    Mo S; Kim MK; Jang JS; Lee SH; Hong SJ; Jung S; Kim HH
    Exp Mol Med; 2024 Aug; 56(8):1791-1806. PubMed ID: 39085359
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of nacreous factors in preventing osteoporotic bone loss through both osteoblast activation and osteoclast inactivation.
    Kim H; Lee K; Ko CY; Kim HS; Shin HI; Kim T; Lee SH; Jeong D
    Biomaterials; 2012 Oct; 33(30):7489-96. PubMed ID: 22809648
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Atypical femur fracture in an adolescent boy treated with bisphosphonates for X-linked osteoporosis based on PLS3 mutation.
    van de Laarschot DM; Zillikens MC
    Bone; 2016 Oct; 91():148-51. PubMed ID: 27477003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.